316. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive or her Department has prepared, commissioned, received, or reviewed any cost-effectiveness analysis, budget impact analysis, or economic model relating to the use of GLP-1 receptor agonist medicines for obesity or weight management, including semaglutide and tirzepatide; whether any such analysis includes modelling of downstream cost offsets relating to type 2 diabetes, cardiovascular disease, or related complications; and if so, to provide the title, authoring body, and completion date of each such analysis. [10655/26]

Summary

316. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive or her Department has prepared, commissioned, received, or reviewed any cost-effectiveness analysis, budget impact analysis, or economic model relating to the use of GLP-1 receptor agonist medicines for obesity or weight management, including semaglutide and tirzepatide; whether any such analysis includes modelling of downstream cost offsets relating to type 2 diabetes, cardiovascular disease, or related complications; and if so, to provide the title, authoring body, and completion date of each such analysis. [10655/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 11 February 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.